Consun Pharmaceutical Group Limited (HKG:1681)

HKG:1681 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	1,269	1,234	2,908	2,748	2,450	2,196
Short-Term Investments	2,752	2,669	958	834.94	589.17	230
Cash & Short-Term Investments	4,021	3,903	3,866	3,583	3,039	2,426
Cash Growth	-0.40%	0.98%	7.88%	17.89%	25.26%	25.05%
Accounts Receivable	291.84	307.72	297.57	255.84	259.56	351.23
Other Receivables	26.25	46.82	72.55	54.13	36.1	18.34
Receivables	318.09	354.54	370.12	309.97	295.66	369.57
Inventory	302.91	303.83	315.51	384.91	287.66	257.62
Restricted Cash	23.45	42.9	-	-	-	2.32
Total Current Assets	4,666	4,605	4,551	4,278	3,623	3,056
Property, Plant & Equipment	928.28	921.17	925.54	863.71	875	858.45
Long-Term Investments	846.23	513.83	29.08	9.23	6.5	-
Other Intangible Assets	263.95	265.61	268.96	283.14	311.9	341.66
Long-Term Deferred Tax Assets	51.84	41.95	12.52	17.84	36.43	46.86
Other Long-Term Assets	75.73	62.71	65.67	55.99	39.87	59.94
Total Assets	6,832	6,410	5,853	5,508	4,892	4,363

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	130.44	130.5	75.64	83.1	59.89	66.64
Accrued Expenses	1,025	910.15	736.12	638.76	566.13	465.53
Current Portion of Long-Term Debt	216.86	200	253.34	503.42	450.52	599.3
Current Portion of Leases	10.56	9.71	6.42	4.22	3.71	3.12
Current Income Taxes Payable	65.87	31.51	47.63	43.38	32.89	2.54
Current Unearned Revenue	55.41	42.57	60.82	17.56	39.98	21.21
Other Current Liabilities	99.87	105.88	190.83	204.57	197.37	199.07
Total Current Liabilities	1,604	1,430	1,371	1,495	1,350	1,357
Long-Term Leases	2.06	3.21	7.41	3.9	5.95	8.55
Long-Term Unearned Revenue	14.96	12.9	14.64	19.18	18.93	16.7
Long-Term Deferred Tax Liabilities	148.97	125.72	67.19	71.21	78.01	69.3
Total Liabilities	1,770	1,572	1,460	1,589	1,453	1,452

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	66.61	67.23	67.31	63.81	63.45	64.8
Additional Paid-In Capital	-	183.8	216.46	18.15	-	19.79
Retained Earnings	-	4,239	3,650	3,381	2,913	2,393
Treasury Stock	-	-114.47	-	-83.17	-83.17	-113.32
Comprehensive Income & Other	4,694	159.42	163.67	247.15	251.7	253.89
Total Common Equity	4,761	4,535	4,098	3,627	3,145	2,618
Minority Interest	300.77	302.84	295.45	292.21	293.87	293.08
Shareholders' Equity	5,062	4,838	4,393	3,919	3,439	2,911
Total Liabilities & Equity	6,832	6,410	5,853	5,508	4,892	4,363

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	229.48	212.92	267.17	511.53	460.18	610.97
Net Cash (Debt)	3,792	3,691	3,599	3,072	2,579	1,815
Net Cash Growth	0.21%	2.56%	17.15%	19.10%	42.08%	30.52%
Net Cash Per Share	4.46	4.32	4.32	3.84	3.26	2.26
Filing Date Shares Outstanding	839.05	840.11	830.83	792.43	788.39	805.64
Total Common Shares Outstanding	839.05	840.11	830.83	792.43	788.39	805.64
Working Capital	3,062	3,174	3,181	2,783	2,272	1,698
Book Value Per Share	5.67	5.40	4.93	4.58	3.99	3.25
Tangible Book Value	4,497	4,269	3,829	3,343	2,833	2,276
Tangible Book Value Per Share	5.36	5.08	4.61	4.22	3.59	2.83
Buildings	-	476.48	399.2	338.28	334.82	334.1
Machinery	-	389.51	363.52	324.86	302.16	282.15
Construction In Progress	-	354.36	412.24	416.43	416.01	381.67

Data Source: S&P Global Market Intelligence Last updated: Aug 26, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Sep 11, 2026

Data Sources Report a data error